Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group
Quach, H.; Joshua, D.; Ho, J.; Szer, J.; Spencer, A.; Harrison, S.; Mollee, P.; Roberts, A.; Horvath, N.; Talaulikar, D.; To, B.; Zannettino, A.; Brown, R.; Catley, L.; Augustson, B.; Jaksic, W.; Gibson, J.; Prince, H. M.
Options for treatment of elderly patients with multiple myeloma have expanded substantially following the development of immunomodulatory drugs (IMiD), proteasome inhibitors and with enhancement in safety of high-dose therapy and autologous stem cell transplant (HDT + ASCT). The recognition of biological heterogeneity among elderly patients has made delivery of therapy more challenging. An individualised approach to treatment selection is recommended in an era in which highly efficacious...[Show more]
|Collections||ANU Research Publications|
|Source:||Internal Medicine Journal|